A phase II study to determine the efficacy and safety of conventional dose oral treosulfan in patients with advanced pre-treated Ewings sarcoma.

Trial Profile

A phase II study to determine the efficacy and safety of conventional dose oral treosulfan in patients with advanced pre-treated Ewings sarcoma.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Treosulfan (Primary)
  • Indications Ewing's sarcoma
  • Focus Therapeutic Use
  • Acronyms OTIS
  • Most Recent Events

    • 19 Sep 2012 Status changed from recruiting to active, no longer recruiting as reported by UKCRN.
    • 09 Sep 2012 Planned End Date changed from 31 Aug 2012 to 14 Sep 2012 as reported by United Kingdom Clinical Research Network.
    • 27 Jul 2012 Accrual to date is 84% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top